New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction
23 Maio 2023 - 9:46AM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, announced results today from its new study,
the Depression Barometer, exploring the state of depression across
the United States. Twenty-one million U.S. adults suffer from major
depressive disorder (MDD)1. According to the survey, 77% of
depression sufferers are either not actively treating their
depression or have completely paused treatment at least once in
their journey, highlighting a hidden epidemic.
Survey results show that 75% of individuals with depression have
undergone some period of treatment with medication and/or non-drug
treatments. Of them, 1 in 4 reported discontinuing or pausing
treatment due to dissatisfaction. Depression medication users, past
and present, appear to have the highest rate of dissatisfaction
with their treatment compared to individuals who received other
options. The number one reason for treatment discontent among
medication users was the adverse impact on their mental health,
followed by the general side effects accompanying treatment and the
negative impact on their physical health. For many depression
sufferers, these adverse side effects were unexpected and directly
prevented them from finding the correct treatment.
“Every patient’s journey with depression is unique, and finding
the right treatments can be a frustrating process of trial and
error,” said Dr. Harold A. Sackeim, Professor, Departments of
Psychiatry and Radiology, Columbia University. “While there is no
one-size-fits-all solution, the findings from this survey reinforce
the importance of physicians educating their patients on all
available treatment modalities with established efficacy, including
a non-drug treatment such as NeuroStar® TMS Therapy, so patients
can work with their doctor to select an appropriate treatment that
gives them the greatest possibility to achieve remission.”
Individuals who have received TMS (transcranial magnetic
stimulation) treatment have a significantly more positive
perspective regarding their treatment journey than those who have
not undergone TMS treatment – according to the survey data, these
patients are 2.5 times more likely to believe they have discovered
the optimal treatment solution for their individual needs. They are
also 3.5 times more likely to feel well-informed about available
depression treatment options than when they first began treatment
and 2.5 times more likely to report a positive experience with
health services related to their depression.
"The findings of this study are significant and underscore the
importance of non-drug treatments in addressing the complex and
persistent nature of depression," said Keith J. Sullivan, President
and CEO of Neuronetics. "Our mission of bringing NeuroStar TMS to
more practices and patients is critical so that they can access an
effective, non-drug treatment without the systemic side effects of
traditional treatments and more importantly, help people find
relief from their symptoms and even save lives in some
cases."
Research MethodThe Depression Barometer is a
quantitative survey that was conducted online within the United
States by Focaldata on behalf of Neuronetics, Inc. from March 23,
2023, through April 6, 2023, among 8,275 adults 18 years of age or
older, gathering data around key areas of mental health with a
focus on national and state-level results. The state-weighted data
collected is intended to reflect the demographics of the overall
adult population in the United States and provide additional
segmentation into certain populations, including ethnic/minority
groups, age groups, genders, and those with a military
affiliation. It is the most recent study of the experience of
depression, its symptoms and severity, treatment, treatment-seeking
behaviors, and barriers to treatment access from the perspective of
depression sufferers.
For more information about NeuroStar, please
visit NeuroStar.com.
About NeuroneticsNeuronetics,
Inc. believes that mental health is as important as physical
health. As a global leader in
neuroscience, Neuronetics is redefining patient and
physician expectations with its NeuroStar Advanced Therapy for
Mental Health. NeuroStar is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication hasn’t helped.
NeuroStar is FDA-cleared for adults with major depressive disorder
(MDD), as an adjunct for adults with obsessive-compulsive disorder
(OCD), and to decrease anxiety symptoms in adult patients with MDD
that may exhibit comorbid anxiety symptoms (anxious depression).
NeuroStar Advanced Therapy is the leading transcranial magnetic
stimulation (TMS) treatment for MDD in adults with over 5.4 million
treatments delivered. NeuroStar is backed by the largest clinical
data set of any TMS system for depression, including the world’s
largest depression Outcomes Registry. Neuronetics is
committed to transforming lives by offering an exceptional
treatment that produces extraordinary results. For safety and
prescribing
information, www.neurostar.com.
About FocaldataFocaldata is a nonpartisan
consumer analytics and public opinion polling company headquartered
in London. It provides advanced polling and market research
software to get highly accurate public opinion data. Their software
handles the complexity of a research project, including audience
sourcing, order fulfillment, data quality, and data processing.
Focaldata is a registered member of the Market Research Society
(MRS) and British Polling Council (BPC). To learn more,
visit www.focaldata.com
References
- National Institute of Mental Health.
(n.d.). Major depression. Retrieved from
https://www.nimh.nih.gov/health/statistics/major-depression
- NeuroStar data on file 2023.
Depression Barometer Survey Results, Focaldata online survey,
3/23/23 – 4/6/23 of 8,275 U.S. adults ages 18+
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Photos accompanying this announcement are available
at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/53b64576-254b-4b34-8221-0d1e12753f7b
https://www.globenewswire.com/NewsRoom/AttachmentNg/eea258b9-4e21-40b8-9d41-3f1d9ce9df5b
https://www.globenewswire.com/NewsRoom/AttachmentNg/9e42892e-e12f-4b4b-8330-866fbc3e97cb
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Neuronetics (NASDAQ:STIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024